Proskauer Advises Celgene Corporation in Its Acquisition of Juno Therapeutics

Andrew Cummings
January 23, 2018

In other Juno Therapeutics news, EVP Robert Azelby sold 1,816 shares of Juno Therapeutics stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36.

Shares of Juno Therapeutics (NASDAQ:JUNO) traded down $3.56 on Wednesday, reaching $67.81. The stock exchanged hands with 8,430,790 numbers of shares compared to its average daily volume of 2.64M shares.

Juno Therapeutics Inc. (NASDAQ:JUNO) touched its 1-Year High price of $74.35 on 01/18/18 and its 1-Year Low price of $19.07 on 01/24/17. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.


Media headlines about Juno Therapeutics (NASDAQ:JUNO) have been trending somewhat positive on Friday, according to Accern. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.07.

Juno Therapeutics Inc. (NASDAQ:JUNO) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The high and low revenue estimates for the current quarter are $24.3 Million and $8 Million, respectively. During the same quarter in the previous year, the company posted ($0.78) EPS.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Thursday, May 4th. In a report released today, Guggenheim analyst Anthony Butler downgraded JUNO to Hold. Raymond James Financial restated a "buy" rating on shares of Juno Therapeutics in a research note on Wednesday. Goldman Sachs Group reiterated a "neutral" rating and set a $44.00 target price on shares of Juno Therapeutics in a research report on Friday, October 6th. Maxim Group reaffirmed a buy rating and issued a $56.00 target price on shares of Juno Therapeutics in a research note on Thursday, November 2nd. The stock now has an average rating of "Hold" and an average target price of $47.26. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5283390096036 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. Capital International Sarl bought 8,600 shares as the company's stock declined 3.53% while stock markets rallied. State Street Corp raised its position in shares of Juno Therapeutics by 16.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 378,195 shares of the biopharmaceutical company's stock valued at $17,288,000 after purchasing an additional 53,821 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Juno Therapeutics by 9.5% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company's stock valued at $160,000 after purchasing an additional 3,559 shares in the last quarter. Finally, Macquarie Group Ltd. grew its holdings in shares of Juno Therapeutics by 17.5% in the third quarter.


Biopharmaceutical company Celgene is buying the remainder of Juno Therapeutics Inc. that it doesn't already own in a deal valued at about $9 billion, which will help it develop medicines for patients with incurable blood cancers.

Celgene will gain access to Juno's pipeline of CAR-T cancer drugs, which are a novel class of therapies that genetically alter patients' immune cells to attack cancer.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER